Activation of NMDA and Non-NMDA receptors by L-aspartate in the suprachiasmatic nucleus of the rat

Cellular Signalling

Volumn 10, Issue 2, 1998, Pages 85-90

  Brautigan, Robert A ^a   Eagles, Douglas A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

AMPA; L aspartate; L glutamate; NMDA; Rat; Suprachiasmatic nucleus

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; ASPARTIC ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; MAGNESIUM ION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOXALINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; ELECTROPHYSIOLOGY; MEMBRANE STEADY POTENTIAL; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SUPRACHIASMATIC NUCLEUS;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ASPARTIC ACID; EXCITATORY AMINO ACID AGONISTS; FEMALE; GLUTAMIC ACID; MALE; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, CELL SURFACE; RECEPTORS, N-METHYL-D-ASPARTATE; SUPRACHIASMATIC NUCLEUS;

EID: 0031983871     PISSN: 08986568     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0898-6568(97)00075-2     Document Type: Article

References (27)

1. Moore R. Y., Eichler V. B. Brain Res. 42:1972;201-206.
2. Stephan F. K., Zucker I. Proc. Natl. Acad. Sci. USA. 69:1972;1583-1586.
3. Klein D. C., Moore R. Y. and Reppert S. M. (1991) Suprachiasmatic Nucleus: The Mind's Clock, 467 pp. Oxford University Press, New York.
4. Vogelbaum M. A., Menaker M. J. Neuroscience. 12:1992;3619-3627.
5. van den Pol A. N. J. Neuroscience. 11:1991;2087-2101.
6. Liou S. Y., Shibata S., Iwasaki K., Ueki S. Brain Res. Bull. 16:1986;527-531.
7. Shibata S., Liou S. Y., Ueki S. Neuropharm. 25:1986;403-409.
8. Cahill G. M., Menaker M. Brain Res. 410:1987;125-129.
9. Kim Y. I., Dudek F. E. J. Physiol. 444:1991;269-287.
10. Shoji S., Hasuo H., Akasu T., Ishimatsu M. The Kurume Medical Journal. 39:1992;129-132.
11. Mayer M., Westbrook G. L., Guthrie P. B. Nature. 309:1984;261-263.
12. Nowak L., Bregestovski P., Ascher P., Herbert A., Prochiantz A. Nature. 307:1984;462-465.
13. Goldstein J. M., Litwin L. C. Mol. Chem. Neuropathol. 18:1993;145-152.
14. Garthwaite J. Br. J. Pharm. 85:1985;297-307.
15. Shibata S., Moore R. Y. Brain Res. 606:1993;259-266.
16. Dudek F. E., Kim Y. I., Bouskila Y. J. Biol. Rhythms. 8(suppl.):1993;S33-S37.
17. Bettler B., Mulle C. Neuropharmacology. 34:1995;123-139.
18. Barbour B., Keller B. U., Llano I., Marty A. Neuron. 12:1994;1331-1343.
19. Sommer B., Keinanen K., Verdoorn T. A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., Seeburg P. H. Science. 249:1990;1580-1585.
20. Curras M. C., Dingledine R. Mol. Pharm. 41:1992;520-526.
21. Fleck M. W., Henze D. A., Barrionuevo G., Palmer A. M. J. Neurosci. 13:1993;3944-3955.
22. Patneau D. K., Mayer M. L. J. Neuroscience. 10:1990;2385-2399.
23. Verdoorn T. A., Kleckner N. W., Dingledine R. Mol. Pharm. 35:1989;360-368.
24. Perkel D. J., Hestrin S., Sah P., Nicoll R. A. Proc. R. Soc. Lond. B(241):1990;116-121.
25. Yuzaki M., Forrest D., Curran T., Connor J. A. Science. 273:1996;1112-1114.
26. Surtees L., Collins G. G. S. Brain Res. 334:1985;287-295.
27. Harrison N. L., Simmonds M. A. Br. J. Pharm. 84:1985;381-391.